Δ40 Isoform of p53 Controls β-Cell Proliferation and Glucose Homeostasis in Mice

Research Division, Joslin Diabetes Center and Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Diabetes (Impact Factor: 8.47). 02/2011; 60(4):1210-22. DOI: 10.2337/db09-1379
Source: PubMed

ABSTRACT Investigating the dynamics of pancreatic β-cell mass is critical for developing strategies to treat both type 1 and type 2 diabetes. p53, a key regulator of the cell cycle and apoptosis, has mostly been a focus of investigation as a tumor suppressor. Although p53 alternative transcripts can modulate p53 activity, their functions are not fully understood. We hypothesized that β-cell proliferation and glucose homeostasis were controlled by Δ40p53, a p53 isoform lacking the transactivation domain of the full-length protein that modulates total p53 activity and regulates organ size and life span in mice.
We phenotyped metabolic parameters in Δ40p53 transgenic (p44tg) mice and used quantitative RT-PCR, Western blotting, and immunohistochemistry to examine β-cell proliferation.
Transgenic mice with an ectopic p53 gene encoding Δ40p53 developed hypoinsulinemia and glucose intolerance by 3 months of age, which worsened in older mice and led to overt diabetes and premature death from ∼14 months of age. Consistent with a dramatic decrease in β-cell mass and reduced β-cell proliferation, lower expression of cyclin D2 and pancreatic duodenal homeobox-1, two key regulators of proliferation, was observed, whereas expression of the cell cycle inhibitor p21, a p53 target gene, was increased.
These data indicate a significant and novel role for Δ40p53 in β-cell proliferation with implications for the development of age-dependent diabetes.

Download full-text


Available from: Bernhard Fidelis Maier, Aug 14, 2015
  • Source
    • "Mice carrying a p53 mutant that cannot be activated by ATM through phosphorylation develop insulin resistance and glucose intolerance, which are associated with a decreased antioxidant function (Armata et al., 2010). Mice that ectopically express D40p53, a p53 mutant that lacks part of the transactivation domain, also exhibit glucose intolerance, hypoinsulinemia, and defects in b cell mass and proliferation, suggesting that p53 plays a role in the regulation of b cell proliferation (Hinault et al., 2011). Conversely, super-p53 mice, which express an additional copy of normally regulated WT p53, have been found to display improved glucose tolerance (Franck et al., 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The function of p53 is best understood in response to genotoxic stress, but increasing evidence suggests that p53 also plays a key role in the regulation of metabolic homeostasis. p53 and its family members directly influence various metabolic pathways, enabling cells to respond to metabolic stress. These functions are likely to be important for restraining the development of cancer but could also have a profound effect on the development of metabolic diseases, including diabetes. A better understanding of the metabolic functions of p53 family members may aid in the identification of therapeutic targets and reveal novel uses for p53-modulating drugs.
    Cell metabolism 08/2013; 18(5). DOI:10.1016/j.cmet.2013.06.019 · 16.75 Impact Factor
  • Source
    • "Volume 3, Number 3, June 2012 265 miR-675 levels increase [102]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Aging is a process that involves all organs and tissues of the human organism. Cells and tissues are impacted by aging in differing degrees, depending on their regenerative potential and sensitivity to outside stimuli. In this review, we discuss the potential role of adult stem cells in the aging process, and the new results that support the role of stem cells in the aging process. Finally, we discuss new evidence from progeroid syndromes that supports the stem cell hypothesis of aging.
    06/2012; 3(3):260-8.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The focus of the 2011 American Aging Association meeting was emerging concepts in the mechanisms of aging. Many of the usual topics in aging were covered, such as dietary restriction (DR), inflammation, stress resistance, homeostasis and proteasome activity, sarcopenia, and neural degeneration. There was also discussion of newer methods, such as microRNAs and genome sequencing, that have been employed to investigate gene expression variance with aging and genetic signatures of longevity. Aging as a field continues to mature, including the following areas: Using a systems approach to tracing conserved pathways across organisms; sharpening definitions of sarcopenia, frailty, and health span; and distinguishing interventions by age tier (early-onset versus late-onset). A preconference session on late-onset intervention concluded that there are numerous benefits to deriving such interventions. Conference talks applied the biology of aging in a translational manner to intervention development. Using an individual's own stem cells to regenerate organs for transplantation and as a cell source for cellular therapies could be a powerful near-term solution to disease. Several proposed interventions were pharmaceutical, myostatin inhibition, losartan, Janus kinase (JAK) pathway inhibitors, and enalapril for frailty and sarcopenia, and metformin to promote the Nrf2 antiinflammation response. In DR, protein restriction was found to be better than general calorie restriction. Short-term fasting may be helpful in chemotherapy, surgery, and acute stress, simultaneously increasing the killing of cancer cells by chemotherapy, while improving the survival of normal cells. Immune system interventions remain elusive, although statins may help to improve cellular senescence promoted bacterial infection. Engineered enzymes may be useful in lysosomal catabolism. Dietary restriction mimetics, most promisingly involving target of rapamycin (TOR; TORC1 inhibition and rapamycin), may be more feasible than dietary restriction.
    Rejuvenation Research 08/2011; 14(4):449-55. DOI:10.1089/rej.2011.1216 · 3.93 Impact Factor
Show more